CSIMarket Company Name, Ticker, Industry, else..
 
Alimera Sciences Inc  (NASDAQ: ALIM)
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 54
 Employees 159
 Revenues (TTM) (Millions $) 98
 Net Income (TTM) (Millions $) -15
 Cash Flow (TTM) (Millions $) -8
 Capital Exp. (TTM) (Millions $) 0

Business Description


Alimera Sciences Inc is a pharmaceutical company that specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company primarily focuses on diseases affecting the retina, such as diabetic macular edema and age-related macular degeneration. Alimera Sciences has developed an implantable drug delivery system called ILUVIEN, which is used to treat these retinal diseases. The company is dedicated to improving the lives of patients with vision impairments and providing innovative solutions in the field of ophthalmology. Alimera Sciences Inc is headquartered in Alpharetta, Georgia, and operates globally in various markets.


   Company Address: 6310 Town Square, Suite 400 Alpharetta 30005 GA
   Company Phone Number: 990-5740   Stock Exchange / Ticker: NASDAQ ALIM


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AZN      0% 
BMY        0.36% 
NVS        4.02% 
REGN        4.22% 
UTHR   -5.4%    
VRTX        0.82% 
• View Complete Report
   



Stocks on the Move

Alimera Sciences Faces Downgrade Amidst Merger Deal and Market Turbulence

Published Wed, Jun 26 2024 1:32 PM UTC

In recent news, Alimera Sciences Inc, a prominent player in the healthcare sector, has experienced a series of significant events that have impacted its financial outlook. These events include a downgrade by HC Wainwright & Co., a merger deal with ANI Pharmaceuticals Inc, and volatility in the market. This article aims to explore the implications of these events for Alimera ...
Shares

Assessing the Impact of Alimera Sciences' Inducement Grants on Company Shares

Published Tue, Jun 4 2024 8:30 PM UTC

Alimera Sciences Reports Inducement Grants: Assessing Impact on Company Shares
Alimera Sciences, a global pharmaceutical company focused on retinal health, recently announced the approval of inducement awards for five non-executive employees. These inducement awards, consisting of stock options under the 2024 Equity Inducement Plan, were granted to new or re-hired employ...
Shares

Alimera Sciences Raises the Stakes: Inducement Grants Create Positive Ripples in Shares

Published Wed, Mar 20 2024 12:00 PM UTC

Alimera Sciences Announces Inducement Grants: What Does This Mean for the Company s Shares?
Alimera Sciences, a leading global pharmaceutical company specializing in retinal health and improving vision, recently made an important announcement regarding inducement grants. These grants were approved under the Alimera Sciences, Inc. 2024 Equity Inducement Plan and were give...
Clinical Study

Advancements in Radiation Retinopathy Treatment: ILUVIEN and Faricimab Injections Show Promise

Published Tue, Mar 19 2024 12:00 PM UTC

Radiation retinopathy is a severe side effect of radiation therapy, causing visual acuity loss and potentially leading to blindness. The groundbreaking research study conducted by the DRCR Retina Network, in partnership with Alimera Sciences, explores the efficacy of ILUVIEN and faricimab (6.0 mg) injections compared to observation in preventing visual acuity loss due to rad...
Clinical Study

Alimera's Breakthrough Synchronicity Study with YUTIQ Surges Past Recruitment Goal: A Game-Changer in Ophthalmology

Published Thu, Jan 4 2024 1:01 PM UTC

Alimera Sciences, a renowned pharmaceutical company specializing in ophthalmic solutions, recently announced the completion of patient recruitment for their groundbreaking Synchronicity Study. This significant milestone marks a major breakthrough in the field of ophthalmology, as the study has successfully surpassed its initial goal of enrolling 100 patients.The Synchronicit...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.68
Working Capital Ratio 3.48
Leverage Ratio (MRQ) 2.36
Total Debt to Equity 1.8
Interest Coverage (TTM) 0.91
Debt Coverage (TTM) 0.19

Per Share Current
Earnings (TTM) -0.39 $
Revenues (TTM) 1.8 $
Cash Flow (TTM) -
Cash 0.2 $
Book Value 0.71 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 616,887
Net Income per Employee (TTM) -92,434
Receivable Turnover Ratio (TTM) 2.81
Inventory Turnover Ratio (TTM) 5.84
Asset Turnover Ratio (TTM) 0.64

Profitability Ratios Current
Gross Margin (MRQ) 88.54 %
Operating Margin (MRQ) -0.29 %
Net Margin (MRQ) -12.65 %
Net Cash Flow Margin (MRQ) -13.32 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -


  Alimera Sciences Inc Outlook

On March 7 2024 the Alimera Sciences Inc provided following guidance

Alimera Sciences Inc. has reported significant growth in its financial perform...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.